Are peptides legal in Indiana?

Can a Indiana resident get peptides by telehealth?

Indiana Code 25-1-9.5 (Telehealth Services and Prescriptions) bars a prescriber from treating or prescribing for a patient located in Indiana by telehealth unless a provider-patient relationship exists, but allows that relationship to be established through telehealth. At a minimum the prescriber must obtain the patient's name, contact information, and location and, as far as reasonably possible, verify identity, must create and keep a medical record, and must notify the patient's primary care provider of prescriptions issued if the patient supplies that contact information. The chapter defines store and forward (transmission of medical information without the patient present) as part of telehealth. Telehealth providers must hold an Indiana license (Indiana is an Interstate Medical Licensure Compact state, which is one route). Section 25-1-9.5-7 also requires the practitioner to obtain informed consent and the medical history needed for a diagnosis, discuss the diagnosis, the evidence for it, and the risks and benefits of treatment options, give follow-up instructions, and provide a visit summary listing any prescription. Section 25-1-9.5-8 lets a prescriber issue a non-opioid prescription to a telehealth patient never examined in person if the standard of care is met, and requires a real-time, two-way audiovisual connection only for controlled substances. The chapter does not say whether an asynchronous-only intake can satisfy the section 7 elements for a first non-controlled prescription, so async_prescribing_allowed is left unknown. [2] [3] [4] [7] [15]

How does the Indiana pharmacy board treat compounding?

The Indiana Board of Pharmacy, administered by the Professional Licensing Agency, regulates pharmacies under Indiana Code Title 25, Article 26 and Title 856 of the Indiana Administrative Code. Indiana follows the federal 503A framework for which substances may be compounded (approved drug component, USP or NF monograph, or FDA 503A bulks list), and Senate Enrolled Act 282 (2026) adds a state layer: bulk drug substances used for compounding must be manufactured by an FDA-registered establishment and be accompanied by a certificate of analysis, with most provisions effective July 1, 2026. The same act creates medical spa registration with the Medical Licensing Board of Indiana starting January 1, 2027, including a responsible practitioner and serious adverse event reporting, which reaches weight-loss and wellness clinics that administer compounded drugs. Pharmacies outside Indiana that ship prescription drugs to Indiana patients must hold an Indiana nonresident pharmacy license under Indiana Code 25-26-17. The enrolled act (Public Law 136, signed March 5, 2026) adds Indiana Code 16-42-22.5, effective July 1, 2026, which bars compounding unless the bulk drug substance is not research grade (outside an IRB-approved study) or veterinary grade, was made by an establishment registered with FDA as a human drug establishment, comes with a valid certificate of analysis stating its identity, content, and country of original manufacture, and has had quality control testing, and unless the compounding complies with the federal Food, Drug, and Cosmetic Act and applicable USP chapters. On Board request, a nonresident pharmacy shipping compounded drugs into Indiana must document compliance, and sellers must keep bulk substance records for two years after the last lot expires. Sterile preparation standards are in the Board's rules at 856 IAC 1, Rule 30 (sterile pharmaceuticals). [1] [5] [6] [8] [9] [10]

Can you get compounded GLP-1s in Indiana?

Compounded semaglutide and tirzepatide are limited to documented patient-specific needs after the FDA shortage allowances ended in 2025, and Indiana's 2026 law adds sourcing rules (FDA-registered bulk manufacturers with certificates of analysis) that exclude the unregistered active ingredient suppliers behind many cheap compounded GLP-1 products. Medical spas offering GLP-1 injections will need to register with the Medical Licensing Board from January 1, 2027. [8] [13]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in Indiana?

Find a provider in Indiana

• Compounding pharmacies in Indiana
• Clinics in Indiana
• Telehealth providers in Indiana

Is it legal to buy research peptides in Indiana?

Only Indiana-licensed pharmacies, including licensed nonresident pharmacies, may dispense prescription drugs to Indiana patients, and Senate Enrolled Act 282 (2026) requires compounders to source bulk substances from FDA-registered establishments. Indiana Code 16-42-22.5, added by that act, expressly bars compounding with a research grade bulk substance outside an IRB-approved study. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and do not meet Indiana's new sourcing standard. [5] [8] [9] [14]

Peptide-specific notes for Indiana

Frequently asked questions

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, and federal FDA guidance.